While these data suggest that CD44 is a key determinant of the phenotypic heterogeneity observed within tumours, it does not appear to reliably identify CSC populations in established cell lines [44], thus raising questions about the suitability of cell lines for the screening of CSC-specific therapies. The gene discussed is CD44; the disease is neoplasm.